Concord Drugs Limited , a pharmaceutical company based in Telangana, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company's performance shows a mixed picture, with improvements in some areas and challenges in others.

Financial Highlights

Key Observations

Revenue and Profitability

• The company's consolidated net sales for the half-year stood at Rs 2,388.25 crore, showing a slight increase over the standalone figure of Rs 2,345.63 crore.
• Concord Drugs reported a consolidated profit after tax of Rs 31.00 crore for the half-year, marginally higher than the standalone profit of Rs 30.53 crore.
• Both standalone and consolidated earnings per share remained consistent at Rs 0.31 for the half-year period.

Balance Sheet Position

• As of September 30, 2025, the company's consolidated total assets stood at Rs 6,861.30 crore, up from Rs 6,514.18 crore as of March 31, 2025.
• The total equity increased to Rs 3,441.89 crore from Rs 3,411.36 crore in the previous fiscal year-end.

Management Commentary

The Board of Directors, in their meeting held on November 13, 2025, approved these unaudited financial results. The results were reviewed by the Audit Committee and audited by Pundarikashyam and Associates, Chartered Accountants.

Investor Information

The company has stated that the financial results are available on its website ( https://concorddrugs.in/investor-relations ) and on the BSE Ltd. website ( www.bseindia.com ). The results will also be published in newspapers as per regulatory requirements.

Concord Drugs Limited, a pharmaceutical company, has reported a strong financial performance for the first quarter. The company's consolidated revenue and profit showed significant growth compared to both the previous quarter and the same period last year.

Revenue Growth

The company's consolidated revenue reached Rs 1,360.64 crore for Q1, marking a substantial increase of 31% from Rs 1,039.17 crore in the previous quarter and 16.4% from Rs 1,169.29 crore in the same quarter last year.

Profit Surge

Concord Drugs' consolidated net profit saw an impressive rise, reaching Rs 11.77 crore. This represents a threefold increase from Rs 3.90 crore in the previous quarter and more than a fourfold jump from Rs 2.73 crore in the corresponding quarter of the previous year.

Standalone Performance

On a standalone basis, the company reported revenue of Rs 1,338.35 crore with a net profit of Rs 11.14 crore for the quarter.

Earnings Per Share

The company's basic earnings per share (EPS) improved to Rs 0.12 for the quarter, reflecting the overall positive financial performance.

Subsidiary Contribution

Concord Drugs' subsidiary, Proton Remedies Private Limited, contributed Rs 40.44 crore to the consolidated revenue and Rs 0.62 crore to the net profit for the quarter.

Financial Stability

The company reported no defaults on loans or debt securities for the quarter, indicating a stable financial position.

Board Approval and Auditor's Review

The Board of Directors approved these unaudited financial results at their meeting. Pundarikashyam And Associates, Chartered Accountants, conducted an independent review of the financial results. They found no material misstatements and confirmed that the results were prepared in accordance with the applicable accounting standards and SEBI regulations.

Concord Drugs Limited's strong performance in Q1 demonstrates significant growth in both revenue and profitability, positioning the company well for the fiscal year ahead.